AU3158900A - Immunogens comprising a peptide and a carrier derived from h.influenzae protein - Google Patents

Immunogens comprising a peptide and a carrier derived from h.influenzae protein

Info

Publication number
AU3158900A
AU3158900A AU31589/00A AU3158900A AU3158900A AU 3158900 A AU3158900 A AU 3158900A AU 31589/00 A AU31589/00 A AU 31589/00A AU 3158900 A AU3158900 A AU 3158900A AU 3158900 A AU3158900 A AU 3158900A
Authority
AU
Australia
Prior art keywords
immunogens
peptide
influenzae protein
carrier derived
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU31589/00A
Inventor
Michel Coste
Yves Lobet
Marcelle Paulette Van Mechelen
Christophe Verriest
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9904412.5A external-priority patent/GB9904412D0/en
Priority claimed from GBGB9904405.9A external-priority patent/GB9904405D0/en
Priority claimed from GBGB9904408.3A external-priority patent/GB9904408D0/en
Priority claimed from GBGB9919260.1A external-priority patent/GB9919260D0/en
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Publication of AU3158900A publication Critical patent/AU3158900A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6068Other bacterial proteins, e.g. OMP
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU31589/00A 1999-02-25 2000-02-22 Immunogens comprising a peptide and a carrier derived from h.influenzae protein Abandoned AU3158900A (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GBGB9904412.5A GB9904412D0 (en) 1999-02-25 1999-02-25 Vaccine
GBGB9904405.9A GB9904405D0 (en) 1999-02-25 1999-02-25 Vaccine
GBGB9904408.3A GB9904408D0 (en) 1999-02-25 1999-02-25 Vaccine
GB9904408 1999-02-25
GB9904412 1999-02-25
GB9904405 1999-02-25
GB9919260 1999-08-13
GBGB9919260.1A GB9919260D0 (en) 1999-08-13 1999-08-13 Vaccine
PCT/EP2000/001457 WO2000050077A1 (en) 1999-02-25 2000-02-22 Immunogens comprising a peptide and a carrier derived from h.influenzae protein d

Publications (1)

Publication Number Publication Date
AU3158900A true AU3158900A (en) 2000-09-14

Family

ID=27451875

Family Applications (1)

Application Number Title Priority Date Filing Date
AU31589/00A Abandoned AU3158900A (en) 1999-02-25 2000-02-22 Immunogens comprising a peptide and a carrier derived from h.influenzae protein

Country Status (6)

Country Link
EP (1) EP1156825A2 (en)
JP (1) JP2002537354A (en)
AR (1) AR022758A1 (en)
AU (1) AU3158900A (en)
CA (1) CA2363118A1 (en)
WO (1) WO2000050077A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK200201741A (en) 2002-11-12 2003-09-16 Statens Seruminstitut Vaccine comprises chimeric malaria proteins derived from Plasmodium falciparum genetically coupled to Plasmodium falcinarum Merozoite surface protein 3
AT413945B (en) * 2003-01-14 2006-07-15 Mattner Frank Dr Use of a compound having a binding capacity to an antibody specific for the natural N-terminal AB42 sequence, for preparing a vaccine for preventing and treating Alzheimer's disease
MY146566A (en) * 2003-12-17 2012-08-30 Wyeth Llc Immunogenic peptide carrier conjugates and methods of producing same
PL2336147T3 (en) * 2003-12-17 2015-01-30 Janssen Alzheimer Immunotherap A beta immunogenic peptide carrier conjugates and methods of producing same
BRPI0806463A2 (en) * 2007-01-15 2011-09-06 Glaxosmithkline Biolog Sa fusion protein, nucleic acid sequence, vector, host cell, vaccine, use of a protein or nucleic acid or vectors, process for producing a fusion protein, and method for treating a cancer patient
WO2011154878A1 (en) * 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
KR20190090775A (en) * 2016-07-21 2019-08-02 백4올 피티이 리미티드 Biofusion Proteins as Anti-malaria Vaccines
US20240245190A1 (en) 2023-01-19 2024-07-25 Sharkninja Operating Llc Identification of hair care appliance attachments

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8713240D0 (en) * 1987-06-05 1987-07-08 Proteus Biotech Ltd Hormones
SE466259B (en) * 1990-05-31 1992-01-20 Arne Forsgren PROTEIN D - AN IGD BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE, AND THE USE OF THIS FOR ANALYSIS, VACCINES AND PURPOSE
BR9707819A (en) * 1996-03-01 1999-07-27 Novartis Ag Peptide immunogens
SE9601158D0 (en) * 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine

Also Published As

Publication number Publication date
WO2000050077A9 (en) 2001-08-16
WO2000050077A1 (en) 2000-08-31
CA2363118A1 (en) 2000-08-31
JP2002537354A (en) 2002-11-05
AR022758A1 (en) 2002-09-04
EP1156825A2 (en) 2001-11-28

Similar Documents

Publication Publication Date Title
AU1951201A (en) Peptide antigens
AU7358700A (en) Dolastatin peptides
AU6173900A (en) Peptide transport
AU6059699A (en) Synthetic peptides, conjugation reagents and methods
AU6045900A (en) Interaction-activated proteins
AU1191001A (en) Plasminogen-like polynucleotides, polypeptides, and antibodies
AU7337400A (en) B7-like polynucleotides, polypeptides, and antibodies
AU4281999A (en) Peptide
AU1582401A (en) Uteroglobin-like polynucleotides, polypeptides, and antibodies
AU3158900A (en) Immunogens comprising a peptide and a carrier derived from h.influenzae protein
AU7335400A (en) Attractin-like polynucleotides, polypeptides, and antibodies
IL141330A0 (en) Dcr5, a bmp-binding protein and aplications thereof
AU2452301A (en) Protein methylarginine-specific antibodies
AU1999999A (en) Contryphan peptides
AU6127498A (en) Msh-receptor subtype selective cyclic peptides
AUPO957397A0 (en) Transporter protein
AU1356401A (en) Follistatin-related protein zfsta4
AU1595299A (en) A carboxy-terminal brca1 interacting protein
AU4778600A (en) Novel polypeptide
AU2094299A (en) Wip, a wasp-associated protein
HK1014964A1 (en) Somatostatin peptides.
GB9908920D0 (en) Peptide
AU1552800A (en) Coupled peptides
AU2109200A (en) Polypeptide
AU2002500A (en) Novel protein

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase